Conformational Radiotherapy of Prostatic Adenocarcinoma at the Dalal Jamm Hospital, Senegal—(Retrospective Analysis of a Series of 62 Cases)
- 1 Radiotherapy Department, Dalal Jamm Hospital, UCAD, Dakar, Senegal
- 2 Preventive Medicine and Public Health Service, Health and Development Institute, UCAD, Dakar, Senegal
- 3 Radiotherapy Department, Dalal Jamm Hospital, UCAD, Dakar, Senegal
- 4 Radiotherapy Department, Dalal Jamm Hospital, UCAD, Dakar, Senegal
- 5 Radiotherapy Department, Dalal Jamm Hospital, UCAD, Dakar, Senegal
- 6 Radiotherapy Department, Dalal Jamm Hospital, UCAD, Dakar, Senegal
Abstract
Aim: We endeavored to describe the epidemiological profile of prostatic cancer, and to evaluate its diagnostic and therapeutic aspects. Method: We conducted a descriptive retrospective study on the conformational radiotherapy of prostatic adenocarcinoma at the Dalal Jamm University Hospital, Senegal from June 2018 to December 2019. We included 62 consecutive patients. The average age of the patients was 68.9 years. The average consultation time was 7.6 months. Results: Symptom manifestation and high PSA triggered the diagnosis of cancer in 74.2% and 25.8% of patients, respectively. Symptoms: pollakiuria (72.3%), bone pain (8%) and erectile dysfunction (4.8%). The digital rectal examination: normal (33.8%), nodular (30.6%), induration (24.1%), and shielding (11.3%). The mean PSA level was 90.6 ng/ml. Histology: adenocarcinoma was the most common (98.6%). The Gleason score: <7 (45.1%), =7 (35.5%), and >7 (19.4%). The majority of patients were in the high-risk group (70.9%) and 7 patients (11.2%) were metastatic at diagnosis. Therapy: first radical prostatectomy (20.9%), first-line curative radiotherapy (67.8%), adjuvant (21%) and palliative radiotherapy in 7 patients (11.2%): patients having received palliative radiotherapy had an estimated decline in symptoms of 80%. Hormone therapy was performed in 88.8% of patients, with average duration of 12.5 months. After a mean follow-up of 15 months, 59 patients were alive, including 45 cases (81.8%) in complete remission; 3 patients with metastasis at the first visit (having received palliative ra diotherapy) died. Conclusion: The collected data show a profile of prostate cancer that is specific to the sub-Saharan context in which the discovery is still late. Also in comparison to developed countries, the therapeutic means necessary to fight against this cancer are limited, even though three-dimensional conformational radiotherapy remains an effective and essential treatment; this study provided fundamental data in the area of insufficient data/tools.
- Catton, C., Gospodarowicz, M., Warde, P., et al. (2001) Adjuvant and Salvage Radiation Therapy after Radical Prostatectomy for Adenocarcinoma of the Prostate. Radiotherapy & Oncology, 59, 51-60. https://doi.org/10.1016/S0167-8140(01)00302-4
- Vassil, A.D., Murphy, E.S., Reddy, C.A., Angermeier, K.W., Altman, A., Chehade, N., et al. (2010) Five Year Biochemical Recurrence Free Survival for Intermediate Risk Prostate Cancer after Radical Prostatectomy, External Beam Radiation Therapy or Permanent Seed Implantation. Urology, 76, 1251-1257. https://doi.org/10.1016/j.urology.2010.01.010
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
- Le cancer de la prostate—Les cancers les plus fréquents. https://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers/Les-cancers-les-plus-frequents/Cancer-de-la-prostate
- International Agency for Research on Cancer (2019) The Global Cancer Observatory: Globocan Senegal 2018. World Health Organisation, Geneva, p. 2. https://gco.iarc.fr/today/data/factsheets/populations/686-senegal-fact-sheets
- Loko, F., Hodonou, R., Akpaka, R., Hounnasso, P., Adisso, S. and Akpo, C. (2011) Valeur prédictive du PSA dans le diagnostic du cancer de la prostate chez les sujets Béninois. International Journal of Biological and Chemical Sciences, 5, No. 2. https://doi.org/10.4314/ijbcs.v5i2.72096
- Salomon, L., Azria, D., Bastide, C., Beuzeboc, P., Cormier, L., Cornud, F., et al. (2010) Recommandations en onco-urologie 2010: Cancer de la prostate. Progrès en Urologie, 20, S217-S251. https://doi.org/10.1016/S1166-7087(10)70042-7
- Catalona, W.J., Partin, A.W., Sanda, M.G., Wei, J.T., Klee, G.G., Bangma, C.H., et al. (2011) A Multi-Center Study of [-2] Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. Journal of Urology, 185, 1650. https://doi.org/10.1016/j.juro.2010.12.032
- Gueye, S.M., Jalloh, M., Iea, L., Niang, L., Kane, R. and Ndoye, M. (2004) Profil clinique du cancer de la prostate au Sénégal. African Journal of Urology, 10, 203-207.
- Tengue, K., Kpatcha, T.M., Botcho, G., Leloua, E., Amavi, A.K., Sikpa, K., et al. (2016) Epidemiological, Diagnostic, Therapeutic and Evolutionary Aspects of Prostate Cancer in Togo. African Journal of Urology, 22, 76-82. https://doi.org/10.1016/j.afju.2015.06.006